Navigation Links
Agilent ChemStation Base Software from Agilent Technologies
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Biology Products:
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Institutes Proteomics Center has published a novel method of ... affinity purifications analyzed by mass spectrometry (APMS) to generate ... associate with one another. The work ... only to the interactions within well-defined protein assemblies, but ...
... resource that identifies regions of the human genome that regulate ... for a number of human diseases, according to researchers at ... majority of DNA in our bodies is packaged, or tightly ... and one of the senior investigators on this study. Our ...
... Mass.--MIT and New York University researchers have identified a ... could be exploited to produce new antibiotics. The ... part of Bacillus anthracis,s defense against the immune response ... that cannot produce NO succumb to the immune system,s ...
Cached Biology News:Stowers Proteomics Center devises method for assigning probabilities to human protein interactions 2Search for the 'on' switches may reveal genetic role in development and disease 2Team IDs weakness in anthrax bacteria 2
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
(Date:6/2/2015)... June 2, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that Dr. Pamela Pavco ... at the 23 rd World Congress ... will include in-depth presentations by world-class clinicians ...
(Date:6/2/2015)... , June 2, 2015 ... the global antibiotic resistance problem  MGB ... class of anti-infectives, to address the major global ... has developed a stable intravenous (IV) formulation of MGB-BP-3, ... resistant Gram-positive hospital-acquired infections.  The intravenous formulation ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3